Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Negative Expression of CPSF2 Predicts a Poorer Clinical Outcome in Patients with Papillary Thyroid Carcinoma.

Thyroid : official journal of the American Thyroid Association - 1 Sept 2015

Sung Tae Yon, Kim Mijin, Kim Tae Yong, Kim Won Gu, Park Yangsoon, Song Dong Eun, Park Su-Yeon, Kwon Hyemi, Choi Yun Mi, Jang Eun Kyung, Jeon Min Ji, Shong Young Kee, Hong Suck Joon, Kim Won Bae

Abstract excerpt

BACKGROUND: The BRAF(V600E) mutation is a promising prognostic biomarker for patients with papillary thyroid carcinoma (PTC), but its prevalence differs widely among different geographic regions. A recent study reported that loss of the Cleavage and Polyadenylation Specificity Factor Subunit 2 (C...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Carcinoma, Papillary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Neoplastic Stem Cells

Share to Republic of Korea

Share to Thyroid Cancer, Papillary

Share to Thyroidectomy

Share to Tissue Array Analysis

Source

Identifiers

PMID: 26148673
DOI: 10.1089/thy.2015.0079

Genes

CPSF2
BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-26148673-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Negative Expression of CPSF2 Predicts a Poorer Clinical Outcome in Patients with Papillary Thyroid Carcinoma.PMID 26148673Read ↗

Neuropilin-2 promotes growth and progression of papillary thyroid cancer cells.Semantic proximity Read ↗

Clinical significance of eukaryotic translation initiation factor 5A2 in papillary thyroid cancer.Semantic proximity Read ↗

PSD3 is an oncogene that promotes proliferation, migration, invasion, and G1/S transition while inhibits apoptotic in papillary thyroid cancerSemantic proximity Read ↗

Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.Semantic proximity Read ↗

MiR-342-3p is a novel biomarker for the diagnosis and regulates tumorigenesis in thyroid papillary cancer through FOXQ1Semantic proximity Read ↗

Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.Semantic proximity Read ↗

Downregulation of CSN 6 attenuates papillary thyroid carcinoma progression by reducing Wnt/ β ‐catenin signaling and sensitizes cancer cells to FH 535 therapySemantic proximity Read ↗

UBE2T promotes PTC progression by activating the JAK/STAT3 pathway via negative regulation of SOCS2Semantic proximity Read ↗

Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.Semantic proximity Read ↗

Microarray analysis of papillary thyroid cancers in Korean.Semantic proximity Read ↗

NR2F1‐AS1 regulated miR‐423‐5p/SOX12 to promote proliferation and invasion of papillary thyroid carcinomaSemantic proximity Read ↗

MicroRNAs miR-146-5p and let-7f as prognostic tools for aggressive papillary thyroid carcinoma: a case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.